PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy By Ogkologos - November 10, 2025 87 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR New Vaccine Stimulates Survivors’ Immune Systems to Keep Triple-Negative Cancer from... February 14, 2020 The Recently Leaked Secret to Marijuana News Discovered April 28, 2023 Lung Cancer Trial of Osimertinib Draws Praise—and Some Criticism July 5, 2023 Utility of Genomic Profiling of cfDNA to Inform Clinical Care for... September 28, 2022 Load more HOT NEWS NHS lung cancer patients in England to get early access to... Preparing for the End of the U.S. Public Health Emergency (PHE):... Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast... How could proposed changes to data protection laws affect research?
